- Home
- NRIX vs BORR Comparison
NRIX vs BORR Comparison
Compare NRIX & BORR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRIX
- BORR
- Stock Information
- Founded
- NRIX 2009
- BORR 2016
- Country
- NRIX United States
- BORR Bermuda
- Employees
- NRIX N/A
- BORR N/A
- Industry
- NRIX Biotechnology: Pharmaceutical Preparations
- BORR Oil & Gas Production
- Sector
- NRIX Health Care
- BORR Energy
- Exchange
- NRIX Nasdaq
- BORR Nasdaq
- Market Cap
- NRIX 1.3B
- BORR 1.3B
- IPO Year
- NRIX 2020
- BORR 2019
- Fundamental
- Price
- NRIX $22.53
- BORR $4.10
- Analyst Decision
- NRIX Strong Buy
- BORR Buy
- Analyst Count
- NRIX 15
- BORR 1
- Target Price
- NRIX $29.33
- BORR $9.00
- AVG Volume (30 Days)
- NRIX 1.1M
- BORR 4.4M
- Earning Date
- NRIX 10-11-2024
- BORR 11-06-2024
- Dividend Yield
- NRIX N/A
- BORR 7.50%
- EPS Growth
- NRIX N/A
- BORR N/A
- EPS
- NRIX N/A
- BORR 0.33
- Revenue
- NRIX $56,424,000.00
- BORR $968,100,000.00
- Revenue This Year
- NRIX N/A
- BORR $33.10
- Revenue Next Year
- NRIX $7.17
- BORR $12.85
- P/E Ratio
- NRIX N/A
- BORR $11.65
- Revenue Growth
- NRIX N/A
- BORR 38.38
- 52 Week Low
- NRIX $5.65
- BORR $3.76
- 52 Week High
- NRIX $29.56
- BORR $7.61
- Technical
- Relative Strength Index (RSI)
- NRIX 36.80
- BORR 36.98
- Support Level
- NRIX $20.65
- BORR $3.83
- Resistance Level
- NRIX $23.09
- BORR $4.23
- Average True Range (ATR)
- NRIX 1.52
- BORR 0.17
- MACD
- NRIX -0.58
- BORR 0.02
- Stochastic Oscillator
- NRIX 14.03
- BORR 26.87
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.
About BORR Borr Drilling Limited
Borr Drilling Ltd is a drilling contractor that owns and operates jack-up rigs of modern and high-specification designs providing drilling services to the oil and gas exploration and production industry. The company operates a fleet of 16 jack-up drilling rigs. Geographically the activities are carried out through Norway.